Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Cohance Lifesciences announced that the United States Food and Drug Administration (USFDA) inspected the Company's formulation (FDF) plant located at Shamshabad, Telangana, from 27 August to 4 September 2026.
The inspection concluded with the issuance of a Form FDA 483 containing four observations.
The Company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline.
In a regulatory filing made on Saturday (05 September 2026), the company informed that the US FDA had inspected the Cohance's formulation (FDF) plant located at Shamshabad, Telangana, from 27 August 2026 to 4 September 2026.
'The company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline,' Cohance Lifesciences said in a statement.
Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global CRDMO formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. It is a technology-driven, integrated CDMO platform offering development and manufacturing solutions across complex APIs, performance materials, agrochemicals, ADCs, oligonucleotides and advanced chemistries for global pharmaceutical and life sciences customers.
The company had reported a consolidated net loss of Rs 24.12 crore in the quarter ended June 2026 as against net profit of Rs 48.88 crore during the previous quarter ended June 2025. Sales declined 23.13% to Rs 422.26 crore in Q1 FY27 as compared with Q1 FY26.
The scrip shed 0.78% to end at Rs 456.55 on the BSE on Friday.
Cohance Lifesciences today announced two proposed transactions to strengthen its Antibody-drug Conjugate (ADC) strategy: an additional investment of USD 13 million in NJ Bio and a controlling investment of USD 5 million in Aruka Bio. Both the transactions will be funded through internal accruals.
Cohance will increase its common-equity ownership in NJ Bio from 56.0% to 67.3%, acquiring the entire holdings of Priyashri Nayak, and the Jain Family Irrevocable Trust. Dr. Jain will retain 32.7%.
Dr. Jain will continue to lead NJ Bio while also advancing Aruka's pipeline and partnership initiatives.
NJ Bio will remain focused on customer-facing contract research, development and manufacturing services. Closer integration will combine its payload-linker and bioconjugation expertise with Cohance's manufacturing capabilities to support customers end-to-end CRDMO development through commercial supply. This integration is expected to strengthen business performance across the combined platform over time.
Aruka Bio, Inc. is a private biotechnology company based in Princeton, New Jersey, focused on developing next-generation antibody-drug conjugates. Its lead program is currently at the preclinical stage.
Cohance's USD 5 million equity investment will fund the buyout of other existing shareholders and convertible noteholders along with working capital.
Following completion and Dr. Jain's upfront equity grant, Aruka will be owned 65% directly by Cohance, 25% by NJ Bio and 10% by Dr. Jain. These percentages are before further dilution from Dr. Jain's performance-linked equity award.
Aruka will become Cohance's direct subsidiary. The investment consolidates control of Aruka's proprietary ADC platform, positioning it to pursue co-development, licensing and other collaborations with pharmaceutical and biotechnology partners as its pipeline progresses.
This follows a review of NJ Bio's performance and integration with Cohance since the original investment in December 2024, which identified an opportunity to strengthen commercial alignment between the two businesses as NJ Bio expands its GMP CDMO services and to give dedicated leadership focus to Aruka's novel drug development pipeline.
Completion is expected by the end of September 2026, subject to definitive agreements, applicable approvals and customary closing conditions.
Neuland Laboratories Ltd, Cohance Lifesciences Ltd, Authum Investment & Infrastructure Ltd, Tata Technologies Ltd are among the other stocks to see a surge in volumes on NSE today, 06 August 2026.
Navin Fluorine International Ltd clocked volume of 29.35 lakh shares by 14:14 IST on NSE, a 21.8 times surge over two-week average daily volume of 1.35 lakh shares. The stock gained 12.73% to Rs.8,578.00. Volumes stood at 1.37 lakh shares in the last session.
Neuland Laboratories Ltd saw volume of 8.36 lakh shares by 14:14 IST on NSE, a 21.66 fold spurt over two-week average daily volume of 38596 shares. The stock increased 7.83% to Rs.21,518.00. Volumes stood at 60067 shares in the last session.
Cohance Lifesciences Ltd saw volume of 49.61 lakh shares by 14:14 IST on NSE, a 17.51 fold spurt over two-week average daily volume of 2.83 lakh shares. The stock increased 2.65% to Rs.440.85. Volumes stood at 3.66 lakh shares in the last session.
Authum Investment & Infrastructure Ltd registered volume of 21.81 lakh shares by 14:14 IST on NSE, a 9.97 fold spurt over two-week average daily volume of 2.19 lakh shares. The stock rose 4.53% to Rs.596.35. Volumes stood at 2.89 lakh shares in the last session.
Tata Technologies Ltd recorded volume of 72.03 lakh shares by 14:14 IST on NSE, a 7.81 times surge over two-week average daily volume of 9.23 lakh shares. The stock gained 5.79% to Rs.797.65. Volumes stood at 3.35 lakh shares in the last session.
Cohance Lifesciences Ltd, CEAT Ltd, Federal Bank Ltd, Jio Financial Services Ltd are among the other stocks to see a surge in volumes on NSE today, 17 July 2026.
Afcons Infrastructure Ltd registered volume of 217.85 lakh shares by 14:14 IST on NSE, a 62.25 fold spurt over two-week average daily volume of 3.50 lakh shares. The stock rose 5.62% to Rs.301.45. Volumes stood at 4.66 lakh shares in the last session.
Cohance Lifesciences Ltd recorded volume of 34.31 lakh shares by 14:14 IST on NSE, a 7.66 times surge over two-week average daily volume of 4.48 lakh shares. The stock lost 0.35% to Rs.440.20. Volumes stood at 3.99 lakh shares in the last session.
CEAT Ltd witnessed volume of 11.7 lakh shares by 14:14 IST on NSE, a 5.73 times surge over two-week average daily volume of 2.04 lakh shares. The stock dropped 7.29% to Rs.3,550.40. Volumes stood at 1.4 lakh shares in the last session.
Federal Bank Ltd recorded volume of 244.88 lakh shares by 14:14 IST on NSE, a 5.22 times surge over two-week average daily volume of 46.94 lakh shares. The stock gained 5.17% to Rs.343.50. Volumes stood at 99.17 lakh shares in the last session.
Jio Financial Services Ltd registered volume of 841 lakh shares by 14:14 IST on NSE, a 4.97 fold spurt over two-week average daily volume of 169.05 lakh shares. The stock rose 2.96% to Rs.242.63. Volumes stood at 96.49 lakh shares in the last session.
Cohance Lifesciences Ltd, Lenskart Solutions Ltd, Carborundum Universal Ltd, Bharti Hexacom Ltd are among the other stocks to see a surge in volumes on BSE today, 09 July 2026.
Acutaas Chemicals Ltd clocked volume of 4 lakh shares by 10:46 IST on BSE, a 12.77 times surge over two-week average daily volume of 31312 shares. The stock lost 1.41% to Rs.3,407.90. Volumes stood at 46484 shares in the last session.
Cohance Lifesciences Ltd registered volume of 3.85 lakh shares by 10:46 IST on BSE, a 9.85 fold spurt over two-week average daily volume of 39024 shares. The stock rose 2.11% to Rs.440.40. Volumes stood at 62127 shares in the last session.
Lenskart Solutions Ltd registered volume of 45.9 lakh shares by 10:46 IST on BSE, a 8.91 fold spurt over two-week average daily volume of 5.15 lakh shares. The stock rose 3.15% to Rs.554.25. Volumes stood at 1.09 lakh shares in the last session.
Carborundum Universal Ltd recorded volume of 52520 shares by 10:46 IST on BSE, a 6.2 times surge over two-week average daily volume of 8469 shares. The stock gained 0.72% to Rs.1,088.20. Volumes stood at 3816 shares in the last session.
Bharti Hexacom Ltd notched up volume of 2.67 lakh shares by 10:46 IST on BSE, a 5.12 fold spurt over two-week average daily volume of 52129 shares. The stock rose 3.87% to Rs.1,579.00. Volumes stood at 12236 shares in the last session.